Publications by authors named "Misba Beerahee"

Claim this Profile
J
Joint longitudinal model-based meta-analysis of FEV and exacerbation rate in randomized COPD trials.
Carolina Llanos-Paez, Claire Ambery, Shuying Yang, Misba Beerahee, Elodie L Plan

J Pharmacokinet Pharmacodyn· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pediatric Population Pharmacokinetic Modeling and Exposure-Response Analysis of Ambrisentan in Pulmonary Arterial Hypertension and Comparison With Adult Data.
Malek Okour, Mita M Thapar, Colm Farrell, Mary Ann Lukas, Maurice Beghetti, Misba Beerahee

J Clin Pharmacol· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An open label trial of nemiralisib, an inhaled PI3 kinase delta inhibitor for the treatment of Activated PI3 kinase Delta Syndrome.
Malcolm Begg, Augustin Amour, Emily Jarvis, Teresa Tang, Sara Santos Franco, Misba Beerahee

Pulm Pharmacol Ther· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Selective androgen receptor modulation for muscle weakness in chronic obstructive pulmonary disease: a randomised control trial.
Divya Mohan, Harry Rossiter, Henrik Watz, Charles Fogarty, Rachael A Evans, Misba Beerahee

Thorax· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improved Confidence in a Confirmatory Stage by Application of Item-Based Pharmacometrics Model: Illustration with a Phase III Active Comparator-Controlled Trial in COPD Patients.
Carolina Llanos-Paez, Claire Ambery, Shuying Yang, Misba Beerahee, Elodie L Plan

Pharm Res· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Longitudinal Model-Based Meta-Analysis of Lung Function Response to Support Phase III Study Design in Chinese Patients With Asthma.
Shuying Yang, Monica Simeoni, Misba Beerahee

Clin Pharmacol Ther· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adaptive study design to assess effect of TRPV4 inhibition in patients with chronic cough.
Valerie J Ludbrook, Kate E Hanrott, James L Kreindler, Joanna E Marks-Konczalik, Nick P Bird, Misba Beerahee

ERJ Open Res· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improved Decision-Making Confidence Using Item-Based Pharmacometric Model: Illustration with a Phase II Placebo-Controlled Trial.
Carolina Llanos-Paez, Claire Ambery, Shuying Yang, Maggie Tabberer, Misba Beerahee

AAPS J· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Investigating the effect of TRPV4 inhibition on pulmonary-vascular barrier permeability following segmental endotoxin challenge.
Sarah Mole, Anya Harry, Andy Fowler, Sarah Hotee, Joseph Warburton, Misba Beerahee

Pulm Pharmacol Ther· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: Bayesian approach to investigate a two-state mixed model of COPD exacerbations.
Anna Largajolli, Misba Beerahee, Shuying Yang

J Pharmacokinet Pharmacodyn· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bayesian approach to investigate a two-state mixed model of COPD exacerbations.
Anna Largajolli, Misba Beerahee, Shuying Yang

J Pharmacokinet Pharmacodyn· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Novel Method for Analysing Frequent Observations from Questionnaires in Order to Model Patient-Reported Outcomes: Application to EXACT® Daily Diary Data from COPD Patients.
Eva Germovsek, Claire Ambery, Shuying Yang, Misba Beerahee, Mats O Karlsson

AAPS J· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population Pharmacokinetic Analysis of Fluticasone Furoate/Umeclidinium/Vilanterol via a Single Inhaler in Patients with COPD.
Rashmi Mehta, Eleni Pefani, Misba Beerahee, Noushin Brealey, Helen Barnacle

J Clin Pharmacol· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dose-response modelling of umeclidinium and fluticasone furoate/umeclidinium in asthma.
Shuying Yang, Navin Goyal, Misba Beerahee, Roopa Trivedi, Laurie Lee

Eur J Clin Pharmacol· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population model of longitudinal FEV1 data in asthmatics: meta-analysis and predictability of placebo response.
Eleonora Marostica, Alberto Russu, Shuying Yang, Giuseppe De Nicolao, Stefano Zamuner, Misba Beerahee

J Pharmacokinet Pharmacodyn· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exploring the roles of UGT1A1 and UGT1A3 in oral clearance of GSK2190915, a 5-lipoxygenase-activating protein inhibitor.
Michael Mosteller, Lynn D Condreay, Elizabeth C Harris, Claire Ambery, Misba Beerahee

Pharmacogenet Genomics· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Does short-term placebo response predict the long-term observation? Meta-analysis on forced expiratory volume in 1 second from asthma trials.
Shuying Yang, Roberto Gomeni, Misba Beerahee

J Clin Pharmacol· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dose response of umeclidinium administered once or twice daily in patients with COPD: a pooled analysis of two randomized, double-blind, placebo-controlled studies.
James F Donohue, Christopher Kalberg, Palvi Shah, Misba Beerahee, Rashmi Mehta

J Clin Pharmacol· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population pharmacokinetics of inhaled umeclidinium and vilanterol in patients with chronic obstructive pulmonary disease.
Navin Goyal, Misba Beerahee, Chris Kalberg, Alison Church, Sally Kilbride

Clin Pharmacokinet· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of capsaicin-driven nasal hyper-reactivity by SB-705498, a TRPV1 antagonist.
Carlijn Holland, Cornelis van Drunen, Jane Denyer, Kevin Smart, Christine Segboer, Misba Beerahee

Br J Clin Pharmacol· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dose response of umeclidinium administered once or twice daily in patients with COPD: a randomised cross-over study.
Alison Church, Misba Beerahee, Jean Brooks, Rashmi Mehta, Palvi Shah

BMC Pulm Med· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Losmapimod concentration-QT relationship in healthy volunteers: meta-analysis of data from six clinical trials.
Shuying Yang, Misba Beerahee

Eur J Clin Pharmacol· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population pharmacokinetics of losmapimod in healthy subjects and patients with rheumatoid arthritis and chronic obstructive pulmonary diseases.
Shuying Yang, Pauline Lukey, Misba Beerahee, Frank Hoke

Clin Pharmacokinet· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, tolerability, pharmacokinetics and pharmacodynamics of GSK2239633, a CC-chemokine receptor 4 antagonist, in healthy male subjects: results from an open-label and from a randomised study.
Anthony Cahn, Simon Hodgson, Robert Wilson, Jonathan Robertson, Joanna Watson, Misba Beerahee

BMC Pharmacol Toxicol· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and pharmacodynamics of mepolizumab, an anti-interleukin-5 monoclonal antibody.
Deborah A Smith, Elisabeth A Minthorn, Misba Beerahee

Clin Pharmacokinet· April 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis